CD274 and renal cell carcinoma: Nonetheless, unlike other immunotherapy-responsive solid tumors, many RCC patients show primary or adaptive resistance and adverse events to ICTs and not all patients show complete responses [5], suggesting a further understanding of PD-1/PD-L1 mediated immunosuppression in RCC is needed to enhance treatment efficacy.